Marex Group’s Propanc Biopharma PPCB Stock Holding History

Marex Group’s Portfolio PPCB Stock Details PPCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.18K	Buy	2,709 +108	+4%	+$641	﹤0.01%	997
2025 Q4	$35.1K	Sell	2,601 -216	-8%	-$5.98K	﹤0.01%	937
2025 Q3	$120K	Buy	+2,817	New	+$182K	﹤0.01%	768

Other funds holding PPCB

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

SCA

Sassicaia Capital Advisers Jericho, New York $88.8M AUM 146.47% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Marex Group's PPCB Position: Q1 2026 in Review

Marex Group increased its Propanc Biopharma (PPCB) stake by 4.2% in Q1 2026, buying an estimated $641 and bringing the position to 2,709 shares worth $7.18K. The position accounts for ﹤0.01% of the portfolio, ranked #997.

Marex Group first reported a position in PPCB in Q3 2025 and has held it in 3 quarters since. The position peaked at $120K in Q3 2025. 6 funds tracked by Wall St. Rank hold PPCB as of Q1 2026.

Marex Group held 2,709 shares of Propanc Biopharma worth $7.18K as of Q1 2026.
Marex Group bought 108 Propanc Biopharma shares in Q1 2026, an estimated $641.
Propanc Biopharma made up ﹤0.01% of Marex Group's portfolio in Q1 2026, its #997 holding.
Marex Group first reported a position in Propanc Biopharma in Q3 2025 and has held it in 3 quarters since.
Marex Group's Propanc Biopharma position peaked at $120K in Q3 2025.
6 funds tracked by Wall St. Rank held Propanc Biopharma as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.